Back to results
US 2024/0181073 A1Published application
Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
OwnerTong Zhu, Alisher B. Khasanov +4inventors
InventorsTong Zhu, Alisher B. Khasanov, Hui Li, Maojun Guo, Yanwen Fu, Yufeng Hong
Life of this patent
Estimating the term…
Abstract
Provided, inter alia, are antibody drug conjugates (ADCs) which specifically bind B Cell Maturation Antigen (BCMA). Further disclosed are pharmaceutical compositions, and methods for treating cancer.
Claims98
An antibody drug conjugate (ADC) of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- Ab is an anti-BCMA, anti-ROR1, anti-CD25, or anti-Claudine 18 antibody;
- m is an integer from 1 to 8;
- L1 is a linker bound to the anti-BCMA, anti-ROR1, anti-CD25, or anti-Claudine 18 antibody;
- L2 is a bond, —C(O)—, —NH—, Amino Acid Unit, —(CH2CH2O)n—, —(CH2)n—, -(4-aminobenzyloxycarbonyl)-,
- —(C(O)CH2CH2NH)—, or combinations thereof;
- wherein n is an integer from 1 to 24;
- and
- D is a drug moiety.
6 more elements
A compound of formula (II):
- or a pharmaceutically acceptable salt thereof, wherein:
- PG is an amine protecting group;
- R11 is H or one or more Amino Acid Units;
- R12 is H or a substituted alkyl, substituted heteroalkyl, substituted heterocycloalkyl, —CO(CH2CH2O)sCH2CH2U, or —CONH(CH2CH2O)sCH2CH2U;
- wherein
- s is an integer from 1 to 24;
- and U is —NH2, —OH, —COOH, or —OCH3.
4 more elements
Dependencies are inferred from the claim text.